Gland Pharma Limited — Others, 31-07-2025: Shareholders meeting

Gland Pharma has announced its 47th Annual General Meeting where shareholders will consider adopting the financial results for FY25 and a final dividend of ₹18 per share. For FY25, the company reported consolidated revenue of ₹5,616.5 Cr and profit after tax of ₹698.5 Cr. Its base business showed strong operational strength with a 35% EBITDA margin, driven by new product launches and 9% US volume growth. R&D investments totaled ₹192.2 Cr. Re-appointment of directors and auditor appointments are also on the agenda.